Physician profile
Robert Sealock
NPI 1831344654
$46,565.72
in general payments reported to CMS, 2019-2025
22 companies · $512 in 2025
The $512 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,249 · 2020: $125 · 2021: $26K · 2022: $12K · 2023: $2,004 · 2024: $2,082 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,376 · Food and Beverage: $2,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,375.75 |
| Food and Beverage | $2,222.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $35,356.12 | 2019-2025 | Conmed Generators, Conmed Biliary, Conmed Hemostasis |
| Olympus Corporation of The Americas | $3,306.87 | 2022-2024 | Single Use Electrosurgical Knife Kd-655, Disposable Distal Attachment, Disposable Biopsy Forceps |
| Ambu INC. | $2,894.13 | 2021-2025 | |
| Pentax of America, INC. | $2,026.59 | 2019 | |
| Boston Scientific Corporation | $1,125.21 | 2019-2025 | Orise, Axios, General - Hemostasis |
| Cook Medical LLC | $479.96 | 2019-2025 | Echotip Insight, Hemospray |
| Abbvie INC. | $419.88 | 2019-2025 | Linzess, Viberzi |
| Erbe USA INC | $150.20 | 2019 | |
| Qol Medical, LLC | $124.99 | 2020 | |
| Gi Supply, INC. | $107.54 | 2019 | |
| Aries Pharmaceuticals, INC. | $100.45 | 2019 | |
| Janssen Biotech, INC. | $82.49 | 2019-2025 | Tremfya |
| Olympus America INC. | $81.10 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.97 | 2024-2025 | Xifaxan |
| Lumendi LLC | $51.61 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $50.03 | 2022 | |
| Merck Sharp & Dohme LLC | $44.67 | 2023 | Dificid |
| Lilly USA, LLC | $31.81 | 2023 | |
| Madrigal Pharmaceuticals | $25.92 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $16.36 | 2024 | Entyvio |
| Laborie Medical Technologies Corp. | $15.06 | 2024 | Alphaone |
| Ardelyx, INC. | $14.76 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sealock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.